Conclusion
Systemic bevacizumab is a promising long-term treatment for severe RRP, with pediatric oncology playing an important role in patient care.
References
  1. Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis.Otolaryngol Clin North Am. 2019;52(4):669-679. doi:10.1016/j.otc.2019.03.011
  2. Buchinsky FJ, Valentino WL, Ruszkay N, et al. Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis. PLoS One. 2019;14(6):e0216697. Published 2019 Jun 13. doi:10.1371/journal.pone.0216697
  3. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev . 2020;86:102017. doi:10.1016/j.ctrv.2020.102017
  4. Barone A, Rubin JB. Opportunities and challenges for successful use of bevacizumab in pediatrics. Front Oncol . 2013;3:92. Published 2013 Apr 29. doi:10.3389/fonc.2013.00092
  5. Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214-221. doi:10.1177/0003489414522977
  6. Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol Suppl. 2009;201:1-13. doi:10.1177/000348940911800901
  7. Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg . 2013;139(5):496-501. doi:10.1001/jamaoto.2013.1810
  8. Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey. Laryngoscope . 2017;127(10):2225-2229. doi:10.1002/lary.26662.
  9. Mohr M, Schliemann C, Biermann C, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.Oncol Lett . 2014;8(5):1912-1918. doi:10.3892/ol.2014.2486
  10. Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope . 2017;127(7):1538-1542. doi:10.1002/lary.26450
  11. Carnevale C, Ferrán-De la Cierva L, Til-Pérez G, et al. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children. Laryngoscope . 2019;129(4):1001-1004. doi:10.1002/lary.27674
  12. Hamdi O, Dome J, Zalzal G, Preciado D. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report.Int J Pediatr Otorhinolaryngol. 2020;128:109706. doi:10.1016/j.ijporl.2019.109706.
  13. Ruiz R, Balamuth N, Javia LR, Zur KB. Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up [published online ahead of print, 2022 Jan 19].Laryngoscope . 2022;10.1002/lary.30021. doi:10.1002/lary.30021
  14. Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: A 2020 perspective. Laryngoscope Investig Otolaryngol . 2021;6(2):340-345. Published 2021 Mar 13. doi:10.1002/lio2.545.
  15. Krstić, M., Pavlović, J., Stanković, P., & Milenković, T. (2014). Etiopathogenesis of recurrent laryngeal papillomatosis and contemporary treatment strategies. Acta medica Medianae, 53(4), 64-74.
  16. Rahbar R, Vargas SO, Folkman J, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol . 2005;114(4):289-295. doi:10.1177/000348940511400407
  17. Enrique OH, Eloy SH, Adrian TP, Perla V. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review. Am J Otolaryngol . 2021;42(5):103126. doi:10.1016/j.amjoto.2021.103126
  18. Allen CT. Biologics for the Treatment of Recurrent Respiratory Papillomatosis. Otolaryngol Clin North Am . 2021;54(4):769-777. doi:10.1016/j.otc.2021.05.002
  19. Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy . 2019;11(15):1337-1351. doi:10.2217/imt-2019-0125
  20. Sidell DR, Balakrishnan K, Best SR, et al. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope . 2021;131(6):E1941-E1949. doi:10.1002/lary.29343